Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammation
Podcast
BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions
BioAge CEO Kristen Fortney sits down with Fierce Editor-in-Chief Ayla Ellison to discuss aging biology, inflammation and NLRP3 drugs.
Ayla Ellison
May 22, 2026 10:00am
BioAge CEO's big plans for 'multi-disease impact' of NLRP3 drug
May 14, 2026 11:00am
Boehringer, Amgen scrap immunology assets, citing low potential
Apr 14, 2026 4:00am
Lipella goes bankrupt, ending mouth inflammation drug ambitions
Mar 31, 2026 7:20am
Rethinking heart attacks as the nervous system gone haywire
Jan 27, 2026 11:00am
JPM26: Gilead eyes new deals from a 'position of strength'
Jan 14, 2026 3:30am
